Ascelia Financial Statements From 2010 to 2025
| ACE Stock | SEK 4.85 0.05 1.04% |
Check Ascelia Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascelia Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Ascelia financial statements analysis is a perfect complement when working with Ascelia Pharma Valuation or Volatility modules.
Ascelia |
Ascelia Pharma AB Company Shares Owned By Insiders Analysis
Ascelia Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Ascelia Pharma Shares Owned By Insiders | 22.73 % |
Most of Ascelia Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascelia Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 22.73% of Ascelia Pharma AB are shares owned by insiders. This is 49.74% higher than that of the Healthcare sector and 60.3% higher than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is 125.27% lower than that of the firm.
Ascelia Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ascelia Pharma's current stock value. Our valuation model uses many indicators to compare Ascelia Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ascelia Pharma competition to find correlations between indicators driving Ascelia Pharma's intrinsic value. More Info.Ascelia Pharma AB is number one stock in return on equity category among its peers. It is rated third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ascelia Pharma's earnings, one of the primary drivers of an investment's value.About Ascelia Pharma Financial Statements
Ascelia Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Ascelia Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Ascelia Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Ascelia Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Ascelia Pharma AB operates as an oncology focused specialty pharmaceutical company that develops medicines to enhance the life expectancy for people living with cancer and cancer-related diseases in Sweden and Denmark. The company was founded in 2000 and is headquartered in Malm, Sweden. Ascelia Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 4 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.